C4 Therapeutics Inc (NASDAQ: CCCC) has experienced a decline in its stock price by -9.17 compared to its previous closing price of 2.18. However, the company has seen a fall of -7.48% in its stock price over the last five trading days. zacks.com reported 2025-03-03 that C4 Therapeutics (CCCC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Is It Worth Investing in C4 Therapeutics Inc (NASDAQ: CCCC) Right Now?
Company’s 36-month beta value is 3.03.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for CCCC is 56.70M, and currently, short sellers hold a 14.42% ratio of that floaft. The average trading volume of CCCC on March 26, 2025 was 1.55M shares.
CCCC’s Market Performance
CCCC’s stock has seen a -7.48% decrease for the week, with a -29.03% drop in the past month and a -49.87% fall in the past quarter. The volatility ratio for the week is 5.99%, and the volatility levels for the past 30 days are at 7.58% for C4 Therapeutics Inc The simple moving average for the past 20 days is -11.39% for CCCC’s stock, with a -58.12% simple moving average for the past 200 days.
Analysts’ Opinion of CCCC
Many brokerage firms have already submitted their reports for CCCC stocks, with Wells Fargo repeating the rating for CCCC by listing it as a “Overweight.” The predicted price for CCCC in the upcoming period, according to Wells Fargo is $12 based on the research report published on December 19, 2024 of the previous year 2024.
Stephens, on the other hand, stated in their research note that they expect to see CCCC reach a price target of $4. The rating they have provided for CCCC stocks is “Equal-Weight” according to the report published on November 18th, 2024.
JP Morgan gave a rating of “Neutral” to CCCC, setting the target price at $6 in the report published on January 29th of the previous year.
CCCC Trading at -32.82% from the 50-Day Moving Average
After a stumble in the market that brought CCCC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.79% of loss for the given period.
Volatility was left at 7.58%, however, over the last 30 days, the volatility rate increased by 5.99%, as shares sank -25.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.71% lower at present.
During the last 5 trading sessions, CCCC fell by -7.94%, which changed the moving average for the period of 200-days by -58.26% in comparison to the 20-day moving average, which settled at $2.23. In addition, C4 Therapeutics Inc saw -45.00% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CCCC starting from Boyle Scott N, who sale 669 shares at the price of $3.15 back on Feb 18 ’25. After this action, Boyle Scott N now owns 107,805 shares of C4 Therapeutics Inc, valued at $2,107 using the latest closing price.
Boyle Scott N, the Chief Business Officer of C4 Therapeutics Inc, sale 490 shares at $3.15 during a trade that took place back on Feb 14 ’25, which means that Boyle Scott N is holding 110,842 shares at $1,544 based on the most recent closing price.
Stock Fundamentals for CCCC
Current profitability levels for the company are sitting at:
- -3.36 for the present operating margin
- 0.83 for the gross margin
The net margin for C4 Therapeutics Inc stands at -2.96. The total capital return value is set at -0.39. Equity return is now at value -45.58, with -29.01 for asset returns.
Based on C4 Therapeutics Inc (CCCC), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -0.99.
Currently, EBITDA for the company is -122.1 million with net debt to EBITDA at -0.1. When we switch over and look at the enterprise to sales, we see a ratio of 4.2. The receivables turnover for the company is 11.47for trailing twelve months and the total asset turnover is 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.71.
Conclusion
In a nutshell, C4 Therapeutics Inc (CCCC) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
